TB-500 vs Astressin-B

TB-500 and Astressin-B represent divergent approaches in peptide research. TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.It contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. Astressin-B, in contrast, is a synthetic cyclic peptide antagonist of corticotropin-releasing factor (CRF) receptors, developed for stress-related research. While TB-500 has progressed to a handful of human randomized controlled trials (RCTs) for wound healing and dry eye, Astressin-B remains preclinical, with its most famous study—a 2011 Salk Institute experiment—showing reversal of stress-induced hair loss in mice. This comparison examines their mechanisms, evidence bases, dosing protocols, and safety profiles to clarify their distinct research niches.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing. Key claims include accelerating wound healing, reducing inflammation, and promoting cardiac repair. The evidence base, while limited, includes controlled human data, which distinguishes it from many research peptides. However, the absence of regulatory approval and the ban in competitive sports underscore its experimental status.

Astressin-B is a synthetic cyclic peptide antagonist of corticotropin-releasing factor (CRF) receptors, originally developed for stress-related research. It gained viral attention after a 2011 Salk Institute study showed that a single injection reversed hair loss in chronically stressed mice. The hair regrowth finding was serendipitous — the study was designed to investigate stress-related GI effects. Despite enormous public interest, no human clinical trials for hair growth have been conducted, and CRF antagonists have a troubled clinical development history for psychiatric indications.

Key claims: Reverses stress-induced hair loss in mice; Blocks CRF-mediated stress response; Reduces stress-induced GI dysfunction.

These peptides target different research areas. TB-500 focuses on injury recovery and anti-inflammatory mechanisms, with applications in wound healing, cardiac repair, and tissue regeneration. Astressin-B targets hair growth and stress research, specifically the CRF-mediated stress response and its downstream effects on hair follicles and gastrointestinal function. There is no significant overlap in their primary research applications. TB-500's evidence base includes human data, while Astressin-B remains confined to animal models. Researchers should select based on their specific experimental endpoints: TB-500 for tissue repair and inflammation studies, Astressin-B for stress physiology and hair growth mechanisms.

TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin beta-4. No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike. Common anecdotal side effects include injection site pain/redness, lightheadedness, mild headache, nausea, and fatigue. Astressin-B: No human safety data exists. CRF receptor antagonism could impair the stress response, which is physiologically essential. Related CRF1-selective antagonists in clinical trials showed hepatotoxicity and limited efficacy. The lack of human data for Astressin-B represents a significant gap, whereas TB-500 has at least preliminary human safety evidence.